Your browser is no longer supported. Please, upgrade your browser.
MRNA Moderna, Inc. daily Stock Chart
Moderna, Inc.
Index- P/E- EPS (ttm)-1.22 Insider Own6.90% Shs Outstand334.89M Perf Week-12.92%
Market Cap6.36B Forward P/E- EPS next Y-1.68 Insider Trans- Shs Float242.45M Perf Month-1.76%
Income-401.90M PEG- EPS next Q-0.38 Inst Own40.80% Short Float5.06% Perf Quarter17.43%
Sales135.10M P/S47.10 EPS this Y-46.90% Inst Trans- Short Ratio11.62 Perf Half Y-
Book/sh4.47 P/B4.25 EPS next Y0.00% ROA- Target Price26.06 Perf Year-
Cash/sh4.54 P/C4.18 EPS next 5Y16.80% ROE- 52W Range13.03 - 24.40 Perf YTD24.43%
Dividend- P/FCF- EPS past 5Y- ROI-26.40% 52W High-22.13% Beta-
Dividend %- Quick Ratio7.00 Sales past 5Y- Gross Margin- 52W Low45.82% ATR1.43
Employees760 Current Ratio7.00 Sales Q/Q-16.70% Oper. Margin- RSI (14)45.58 Volatility6.52% 7.48%
OptionableYes Debt/Eq0.02 EPS Q/Q-100.30% Profit Margin- Rel Volume0.55 Prev Close19.34
ShortableYes LT Debt/Eq0.02 EarningsMar 06 BMO Payout- Avg Volume1.06M Price19.00
Recom1.80 SMA20-9.75% SMA501.76% SMA2005.60% Volume579,016 Change-1.76%
Mar-20-19 08:24AM  Cambridge VC Flagship raises $824M for new life science investments American City Business Journals
Mar-13-19 08:48PM  Moderna Inc (MRNA) Files 10-K for the Fiscal Year Ended on December 31, 2018
10:27AM  How Much Of Moderna, Inc. (NASDAQ:MRNA) Do Insiders Own? Simply Wall St.
Mar-06-19 07:00AM  Moderna Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights Recent Pipeline Progress Business Wire
Mar-04-19 07:04PM  Cramer: Investors can find a better entry point on these recent IPOs CNBC Videos -5.16%
05:30PM  Moderna to Present at Upcoming Investor Conferences in March Business Wire
Feb-21-19 04:15PM  Moderna to Report Fourth Quarter and Full Year 2018 Financial Results on Wednesday, March 6, 2019 Business Wire
Feb-20-19 05:00AM  Phase 1 Data Published in Nature Communications Show Potential of mRNA Encoding VEGF-A as a Regenerative Therapeutic Business Wire
Feb-19-19 05:12PM  Andreas Halvorsen's 5 Largest Stock Buys in 4th Quarter
Feb-14-19 01:17PM  Moderna's Small Base Could Surprise on the Upside +6.10%
12:01PM  Is Moderna a Buy? Motley Fool
Feb-13-19 07:49AM  The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering Benzinga
Feb-12-19 04:23PM  Moderna reports early success in respiratory infection vaccine American City Business Journals
04:01PM  Moderna Announces Positive Interim Phase 1 Data for First Combination Vaccine Against the Respiratory Viruses hMPV and PIV3 Business Wire
Feb-06-19 07:48AM  Cancer-Vaccine Maker BioNTech Considering an IPO in U.S. Bloomberg +5.59%
Feb-05-19 08:30AM  Moderna Announces Dosing of the First Monoclonal Antibody Encoded by mRNA in a Clinical Trial Business Wire +5.59%
Feb-01-19 06:46PM  Cramer's lightning round: Bank of America's stock is a screaming buy CNBC
Jan-31-19 04:37PM  Here's Why Moderna Jumped 9.7% on Thursday Motley Fool +9.72%
07:55AM  Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and Moderna ACCESSWIRE
Jan-30-19 02:00PM  Newly Published Pre-Clinical Data Show Intratumoral Injections of Messenger RNA Encoding Three Immune Modulators Stimulate Durable Anti-Cancer Responses in Treated and Distal Tumors Business Wire
Jan-24-19 02:30PM  Moderna's Hot New mRNA Technology Has Competition Motley Fool
Jan-18-19 08:00AM  Dr. John Mendlein to Transition to an Advisory Role at Moderna and Join Flagship Pioneering as an Executive Partner Business Wire
Jan-14-19 08:00AM  Today's Research Reports on Trending Tickers: Moderna and Neurocrine Biosciences ACCESSWIRE
Jan-09-19 04:05PM  Moderna, MyoKardia Are Among Cutting-Edge Biotech Stocks for 2019
12:13PM  Moderna Soars After Update of Its Pipeline Programs
10:04AM  Moderna (MRNA) Announces Pipeline Progress, Shares Rise Zacks
Jan-08-19 04:29PM  This New Biotech Stock Is Popping Will It Reclaim Its IPO Price? Investor's Business Daily
03:07PM  Moderna announces plans to bring three new drugs to clinic American City Business Journals
11:07AM  Moderna Shares Jump on Positive Cancer-Treatment Progress
08:48AM  Moderna's stock jumps after progress report on cancer treatments MarketWatch
08:45AM  Moderna CEO discusses company innovation following IPO CNBC Videos
08:30AM  Moderna Announces Recent Progress in Its Immuno-Oncology and Rare Disease Programs and Highlights Corporate Objectives Business Wire
Jan-07-19 04:53PM  Biotech's big conference living up to reputation with big deals, big costs American City Business Journals
Jan-03-19 02:37PM  Analysts Issue New Ratings on Large Health Care Stocks
Jan-02-19 04:30PM  Morgan Stanley: Moderna Has Significant Competitive Advantage Benzinga
04:27PM  Could This New Biotech IPO Could Score Big With A Cancer Vaccine? Investor's Business Daily
04:15PM  Moderna to Provide Business and Pipeline Updates at the 2019 J.P. Morgan Healthcare Conference Business Wire
Dec-31-18 09:49AM  Moderna Analysts Plan Reckoning After Valuation Declines Bloomberg +7.92%
Dec-27-18 11:47AM  Andreas Halvorsen Invests in Biotech Company Moderna +8.36%
10:22AM  10 Hot Companies Going Public in 2019 InvestorPlace
Dec-21-18 05:20PM  Gossamer Bio files for IPO MarketWatch -6.65%
03:15PM  Alector, Gossamer chase Moderna with biotechnology IPOs-sources Reuters
Dec-18-18 12:41PM  IPO activity next year could dampen if markets do not rebound- report Reuters
Moderna, Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, and cardiovascular diseases. As of February 15, 2019 the company had 11 programs in clinical trials and a total of 20 development candidates in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics. It has strategic alliances with AstraZeneca, Merck & Co., Vertex Pharmaceuticals, Biomedical Advanced Research and Development Authority, Defense Advanced Research Projects Agency, and Bill & Melinda Gates Foundation. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.